suven life sciences filed its Business Responsibility and Sustainability Report (BRSR) for FY26 with the Bombay Stock Exchange and the National Stock Exchange on July 30, 2026. The filing, mandated under Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, reveals that exports constitute 70% of the company’s total turnover, serving markets in four international countries alongside domestic operations in two Indian states. This high export dependency underscores the company’s integration into global pharmaceutical supply chains, where regulatory compliance and safety standards are critical for sustaining revenue streams.

The report covers standalone operations and was assured by J. Sundharesan & Associates, which provided limited assurance on the working of the company’s policies. Suven Life Sciences operates three plants and one office nationally, with no international facilities. The company’s primary business activity is scientific research and development, accounting for 100% of its turnover. CSR provisions under Section 135 of the Companies Act, 2013 are not applicable as the company does not meet the specified thresholds.

Workforce and Human Capital

As of the end of FY26, the company employed 142 permanent employees, comprising 102 males and 40 females, along with 39 non-permanent workers. The Board of Directors includes two women, representing 33.33% of the total board strength. Key Management Personnel (KMP) includes one female member, accounting for 50% of the KMP group.

The permanent employee turnover rate for FY26 stood at 9.28%, a significant decline from 19% in FY25 and 24% in FY24. This reduction suggests improved retention strategies or stabilization in workforce dynamics. The company reported no differently abled employees or workers. All permanent employees and non-permanent workers received health insurance coverage. Additionally, 100% of permanent employees underwent performance and career development reviews.

Environmental and Safety Metrics

The company reported total energy consumption of 6,635.70 Gigajoules in FY26, an increase from 5,606.06 Gigajoules in FY25. All energy consumed was from non-renewable sources. Greenhouse gas emissions totaled 1,340.76 metric tonnes of CO2 equivalent, combining Scope 1 emissions of 45.00 metric tonnes and Scope 2 emissions of 1,295.76 metric tonnes. This represents an increase from the previous year’s total of 915.60 metric tonnes.

Water withdrawal amounted to 2,007.50 kilolitres, primarily from third-party sources, with consumption at 1,807.5 kilolitres. Waste generation increased slightly to 11.347 metric tonnes, consisting mainly of bio-medical waste (11.172 metric tonnes) and battery waste (0.175 metric tonnes). All waste was disposed of via incineration. No safety-related incidents, fatalities, or lost-time injuries were reported during the year.

Governance and Risk Management

The Board of Directors oversees sustainability issues, with Chairman and Managing Director Venkateswarlu Jasti responsible for BRSR matters. The company aligns its policies with National Guidelines on Responsible Business Conduct (NGRBC) and holds NABL accreditation for its laboratory. Material risks identified include clinical trial failures and drug safety monitoring issues, both carrying negative financial implications. The company mitigates these through proactive risk assessment, qualified investigative teams, and independent Data Safety Monitoring Boards during Phase 2 and Phase 3 trials.

No fines, penalties, or disciplinary actions for bribery or corruption were recorded. The company maintains an anti-corruption policy and a whistle-blower mechanism. Zero complaints related to sexual harassment, discrimination, or human rights violations were filed in FY26.

Suven Life Sciences Limited has issued the notice for its 37th Annual General Meeting (AGM), scheduled to be held on Tuesday, August 25, 2026, at 11:30 a.m. IST through Video Conferencing (VC) / Other Audio Visual Means (OAVM). The meeting will address critical corporate governance matters, including a material related party transaction involving the appointment of Dr. Madhavi Jasti, the re-appointment of an Independent Director beyond the age of seventy-five, and a significant reallocation of unutilised proceeds from a recent preferential issue. These developments signal the company's strategic focus on strengthening its overseas clinical development capabilities while optimising capital deployment amidst a widening standalone loss of ₹5,486.28 lakhs in FY26.

Related Party Transaction: Appointment of Dr. Madhavi Jasti

The Board seeks shareholder approval for the appointment of Dr. Madhavi Jasti, daughter of Chairman & Managing Director Mr. Venkateswarlu Jasti and Whole-time Director Mrs. Sudha Rani Jasti, to oversee Medical Affairs in the company’s wholly owned subsidiaries in the USA and Singapore. This engagement qualifies as a Material Related Party Transaction under Regulation 23(4) of SEBI LODR because her proposed annual remuneration exceeds 10% of the company’s consolidated turnover.

Dr. Jasti, who holds 1,000 equity shares in the listed entity, will be responsible for clinical trials, medical monitoring, and regulatory compliance. Her initial remuneration is set at USD 400,000 per annum, with a maximum ceiling of USD 1,000,000 per annum, payable by the overseas subsidiaries. The Board justified the appointment based on her MD degree from the USA and over ten years of experience in clinical development, stating that the arrangement is at arm’s length and in the ordinary course of business. Promoter directors and their relatives are barred from voting on this resolution.

Variation in Utilisation of Preferential Issue Proceeds

Shareholders will also vote on a special resolution to vary the utilisation of proceeds from the preferential issue of 6,40,02,999 convertible warrants raised at ₹134 per warrant, aggregating ₹857.64 crores. As of March 31, 2026, only ₹26,068.64 lakhs had been utilised, leaving an unutilised balance of ₹59,695.38 lakhs. The company proposes to reallocate funds primarily due to lower-than-expected capital expenditure for its new R&D centre in Genome Valley, Hyderabad, and increased funding requirements for clinical development programs.

The revised allocation shifts ₹7,500.00 lakhs from the CAPEX object (reduced from ₹20,000.00 lakhs to ₹12,500.00 lakhs) to clinical development expenses (increased from ₹40,000.00 lakhs to ₹47,500.00 lakhs). This reallocation aims to support the expansion of clinical trial activities across multiple jurisdictions without altering the fundamental purpose of the fund raise. CRISIL Ratings Limited continues to monitor the utilisation of these proceeds.

Board Re-appointments and Governance

The AGM agenda includes the re-appointment of Prof. Seyed E. Hasnain as a Director retiring by rotation. Additionally, shareholders must approve the re-appointment of Dr. Vajja Sambasiva Rao as an Independent Director for a second consecutive term of five years, commencing January 21, 2027. This requires a Special Resolution because Dr. Rao will attain the age of seventy-five years on January 21, 2027, necessitating justification under Regulation 17(1A) of SEBI Listing Regulations. The Board cited his extensive experience in project management and corporate governance as key reasons for retaining him beyond the standard age limit.

Financial Context and E-Voting Details

The corporate actions come against a backdrop of significant financial losses. Suven Life Sciences reported a standalone loss of ₹5,486.28 lakhs in FY26, up from ₹4,707.98 lakhs in FY25, driven by high R&D expenditures. The consolidated loss widened to ₹27,634.41 lakhs, largely attributable to clinical development costs incurred by its US subsidiary. No dividend was recommended for FY26.

Remote e-voting for the AGM will commence on Friday, August 21, 2026, at 9:00 a.m. IST and conclude on Monday, August 24, 2026, at 5:00 p.m. IST. The cut-off date for determining voting rights is Tuesday, August 18, 2026. Members holding shares as on this date are eligible to cast their votes electronically through the KFin Technologies Limited platform.